Mar. 10, 2025-- Corcept Therapeutics Inc., a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, recently announced the initiation of Momentum, a clinical trial examining the prevalence of endogenous hypercortisolism (Cushing’s syndrome) in patients with resistant hypertension. 

March 11, 2025 — The disparities between men and women in prevalence, risk factors and symptoms of peripheral vascular disease (PVD) have a profound impact on prevention, diagnosis, treatment and outcomes for women, according to a new American Heart Association scientific statement published today in the Association’s flagship, peer-reviewed journal Circulation.

March 11, 2025 — Caristo Diagnostics has received U.S. Food and Drug Administration (FDA) 510(k) clearance of its CaRi-Plaque technology, an AI-assisted image analysis application to aid the diagnosis of coronary artery disease (CAD).

At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., Medtronic presented new data and clinical milestones across its Coronary, Structural Heart and Renal Denervation businesses.  The conference will showcase key data presentations and advancements across its Coronary, Structural Heart and Renal Denervation businesses in the Medtronic Cardiovascular portfolio. Additionally, Geoff Martha, chief executive officer and chairman at Medtronic, also provided the industry keynote, addressing the company's commitment to advancing cardiovascular care.

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association 2025 Heart Disease and Stroke Statistical Update. Additionally, data from the Statistical Update shows that more than 28 million people worldwide are living with some type of heart valve disease, an increase of more than 30% in the past decade.

36th Annual Cardiovascular Interventions

March 3, 2025 — Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for treating acute ischemic stroke (AIS) in adults. This approval is Genentech’s second approval for stroke, and the company is now the developer of the only two FDA-approved medicines for AIS, TNKase and Activase (alteplase).

March 1, 202 — One in three people worldwide will develop a potentially life-threatening heart rhythm disorder in their lifetime, yet awareness remains critically low. On March 1 — Pulse Day (Global Arrhythmia Awareness Day) — cardiologists from the European Heart Rhythm Association (EHRA) urged communities and healthcare systems to "Feel the Pulse" and take simple steps to raise awareness of these serious but often overlooked conditions.

Feb. 25, 2025— GE HealthCare has delivered the first patient doses of Flyrcado (flurpiridaz F 18) injection, a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD), at early adopter imaging centers in the US. This  follows the recent FDA approval of Flyrcado, which is indicated for patients with known or suspected CAD, and delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI..

March 3, 2025 — Eko Health has published a peer-reviewed study in JACC Advances evaluating its 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now